Pilocarpine is a cholinergic parasympathomimetic alkaloid which acts as a non-selective muscarinic receptor agonist. It is used ophthalmically as a miotic in chronic simple glaucoma, acute (closed-angle) glaucoma, and orally in the treatment of severe xerostomia and Sjögren’s syndrome.
There are no published epidemiological studies on the use of pilocarpine during pregnancy and an evidence-based evaluation of risk to the fetus with maternal use during pregnancy is not currently possible. However, when pregnancy is being considered, any theoretical risks to the fetus should be weighed against the potential adverse effects (including permanent loss of vision) for the mother from untreated glaucoma.
Exposure to pilocarpine at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy. However, due to the lack of data and as other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome, the need for additional fetal monitoring should be decided on a case-by-case basis. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.
This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.
If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.
If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.